Lineage Cell Therapeutics... (LCTX)
AMEX: LCTX
· Real-Time Price · USD
1.54
0.15 (10.79%)
At close: Sep 18, 2025, 3:59 PM
1.55
0.32%
After-hours: Sep 18, 2025, 07:57 PM EDT
10.79% (1D)
| Bid | 1.49 |
| Market Cap | 352.81M |
| Revenue (ttm) | 10.91M |
| Net Income (ttm) | -40.91M |
| EPS (ttm) | -0.17 |
| PE Ratio (ttm) | -9.09 |
| Forward PE | -19.71 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.55 |
| Volume | 3,577,450 |
| Avg. Volume (20D) | 2,241,953 |
| Open | 1.43 |
| Previous Close | 1.39 |
| Day's Range | 1.40 - 1.61 |
| 52-Week Range | 0.37 - 1.61 |
| Beta | 1.67 |
| Ex-Dividend Date | n/a |
About LCTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LCTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LCTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsLineage Cell Therapeutics Inc. is scheduled to release its earnings on
Nov 13, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
10 months ago
-28.99%
Lineage Cell Therapeutics shares are trading lower...
Unlock content with
Pro Subscription
2 weeks ago · businesswire.com
Lineage Cell Therapeutics to Present at September 2025 Investor ConferencesCARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
